Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Monday, December 17, 2018 · 471,365,397 Articles · 3+ Million Readers

2-Day Course: Common Technical Document (London, United Kingdom - December 4-5, 2019)

/EIN News/ -- Dublin, Dec. 07, 2018 (GLOBE NEWSWIRE) -- The "Common Technical Document" conference has been added to's offering.

This two-day course will provide you with a clear understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of EU and USA. Furthermore, the course examines the requirements for global roll out of the document to ROW regions including, LATAM, ASEAN, MENA and CIS territories.

You will increase your ability to manage all aspects of development of the CMC applications after two days of intensive lectures, group work, and discussion session, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier.

This course will cover the following topics:

  • Effective compilation of CTD and critical review of documentation
  • Quality by design, critical attributes and developing new product using the CQA pyramid model
  • Compiling and submitting Module 3 (CTD) of your registration dossier
  • Identifying the extent of content expected by EU and US regulators
  • Achieving the quickest turnaround of your submission
  • Managing the pharmaceutical development and quality aspects of your developments and registration dossier in Europe and US
  • Ensuring right first time development
  • Meeting the legal framework and guidelines for the CMC/quality part of the document, and links to GMP


Programme Day One

What is the CTD? The road map to Module 3 Understanding ICH

Assessing the impact of the harmonisation - ICH guidelines

Preparing the drug substance section of the application - US and EU

  • Analysing the needs for the section
  • How to submit information - Drug Master Files, Certificates of Suitability, other methods
  • European Submissions, CEP and ASMF requirements
  • Detailed information requirements for the section
  • Q11 explained - EU and US expectations of FMEA analysis
  • Development expectations and scale-up requirements
  • Specific examples on EU / US format and guidance

GMP for Active Substances

  • Examining GMP requirements and EU and US expectations, inspection timing and interactions and contractual obligations

Case study: Essential information from API suppliers

  • The case study will allow participants to identify and understand the essential data requirements from API suppliers for submission of generic applications

Examining the content of the sections concerning the drug product. Composition and development of the drug product

  • Defining the formulation
  • Identifying the data needs for the pharmaceutical development section, explaining QBD and FMEA requirements
  • Multiple examples of Development Report content - practical for table of contents and creation of QBD Pyramid

Programme Day Two

(All Module Sections include Example Sections for Writing)

Writing the section on manufacture of the drug product and process validation

  • Examining the content of the section: How much information to provide
  • Defining the difference between process development and validation and looking at validation expectations in today's environment
  • Examining the content of the section

Writing the sections on Excipients and Packaging Components

  • Control of the Excipients/Packaging Components
  • Examples of data expectations
  • Examining maintaining these sections

Writing the sections on control of the finished product and Case Study

  • Examining the content of the section
  • Control of the drug product
  • Examples of specifications for Multiple Product Types
  • Examples for Method Summaries

Writing the stability section

  • Examining the content of the section
  • Evaluation of stability data and the impact on shelf

The function and content of the Quality Overall Summary

  • Overview of the current approaches
  • What is the Expert Report: Practical involvement of the expert
  • QOS explained and compared with Expert Report
  • Detailed content of the QOS

Examining Global Roll-out of CTD - Module 3

Examining Change Control - Practical tips

Practical Exercise in Generic Development

  • Identifying 10 - stage plan for developments

For more information about this conference visit

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Drug Discovery


Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release